A multimodal MRI radiomics and deep learning model outperformed traditional models in predicting 5- and 7-year survival for breast cancer patients receiving neoadjuvant chemotherapy.
Key Details
- 1Study involved 216 women with breast cancer post-neoadjuvant chemotherapy.
- 2Model integrated MRI radiomics, pathology, and clinical data using deep learning.
- 3The deep feature-based patho-radiomic model achieved AUCs of 0.89 (training) and 0.82 (test) for 5-year survival, and 0.91 (training) and 0.87 (test) for 7-year survival.
- 4Clinical-only models showed lower AUCs (0.4–0.53 for 5-years; 0.45–0.53 for 7-years).
- 5Traditional clinical and molecular markers (ER, HER2, TNBC) did not significantly predict survival in this cohort.
- 6Authors advocate for prospective studies to guide clinical decisions using the model.
Why It Matters
This research demonstrates the power of combining imaging, pathology, and clinical data through AI to provide more accurate long-term prognostic tools in oncology, surpassing traditional clinical or single-modality models. Improved risk stratification could optimize therapeutic decision-making and patient counseling in breast cancer care.
Source
AuntMinnie
Related News
•AuntMinnie
Study: Patients Prefer AI in Radiology as Assistive, Not Standalone Tool
Survey finds patients support AI-assisted radiology but not AI-only interpretations.
•AuntMinnie
AI-Enhanced MRI Boosts Return-to-Play Predictions for Athlete Muscle Injuries
Adding AI to MRI-based classification systems improves return-to-play predictions for professional athletes with muscle injuries.
•HealthExec
AI's Expanding Role in Healthcare and Implications for Radiology
A series of thought leaders and institutions weigh in on AI's transformative potential in healthcare, with emphasis on radiology adoption and responsible use.